
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics Inc is poised for revenue growth, with an anticipated total revenue increase of approximately 6% year-over-year in 2026, driven predominantly by a 10% growth in its prenatal testing segment and steady mid-single-digit growth in hereditary cancer testing, tumor profiling, and pharmacogenomics, thanks to rising test volumes. The company's strategic focus on enhancing its oncology portfolio over the next 12-18 months through the launch of innovative products, such as Precise MRD and AI-enabled Prolaris, indicates a commitment to strengthening its market position. Furthermore, the upcoming debut of the RiskScore expanded panel for MyRisk and the introduction of Precise Liquid also position Myriad Genetics favorably within the evolving landscape of cancer care and diagnostics.
Bears say
Myriad Genetics Inc. is facing a negative outlook as reflected by recent downgrades to Sector Perform and a reduction in the price target to $6, indicating concerns about its financial performance and market position. The company's reliance on its molecular diagnostics offerings, while innovative, may not be fostering the robust growth needed to meet investor expectations, as suggested by the repeated downgrades. Additionally, potential challenges in competitive market dynamics and revenue generation from its diagnostic services could further impact the company's financial stability and growth trajectory.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares